News/Events
Subscribe to get latest news
News
Flamingo Therapeutics Announces Poster Presentation on FTX-001 at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Flamingo Therapeutics (“Flamingo”) today announced a presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida.
Flamingo Therapeutics Announces Appointment of Andrew E. Denker, MD, PhD, as Chief Medical Officer
Dr. Denker is a physician-scientist with over two decades of biotech and pharmaceutical industry experience in clinical development across multiple modalities and therapeutic areas, including oncology and rare disease.
Flamingo Therapeutics and Dynacure Announce Merger to Create Leading RNA Therapeutics Company Focused on Clinical Oncology
Flamingo Therapeutics (“Flamingo”) and Dynacure, announced today that the companies have signed a definitive merger agreement to combine their pipelines and expertise to create a leading oncology company.
Flamingo Therapeutics to Present at the BioEquity Europe and Knowledge for Growth Conferences in May 2022
Flamingo Therapeutics, a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that Mike Garrett, Chief Executive Officer, will present a company ...
Flamingo Therapeutics to Present at BioCapital Europe 2022
Flamingo Therapeutics., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that Mike Garrett, Chief Executive Officer and Rob MacLeod, ...
Flamingo Therapeutics to Present at the Chardan Virtual 5th Annual Genetic Medicines Conference
Flamingo Therapeutics., a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that Mike Garrett, Chief Executive Officer and Rob MacLeod, ...